NasdaqGS:HUMABiotechs
Humacyte (HUMA) Is Up 23.8% After New ATEV Self‑Repair Data And Phase 3 Timeline Update
Humacyte recently reported research from its acellular tissue engineered vessel (ATEV) program showing long-term structural integrity and self-repair after years of repeated dialysis cannulation, alongside reduced infection susceptibility versus ePTFE grafts, and confirmed that top-line Phase 3 V012 dialysis access results are scheduled for release on June 11, 2026.
Together with ongoing late-stage trials and an approved vascular trauma indication, the ATEV’s self-repair profile highlights...